PD-L1 positive gastric cancer
Showing 1 - 25 of >10,000
Metastatic Gastric Cancer, PD-L1 Gene Amplification, FGFR2 Amplification Trial in New York (Nivolumab, Capecitabine,
Recruiting
- Metastatic Gastric Cancer
- +2 more
- Nivolumab
- +2 more
-
New York, New YorkBureau for Cancer Research
May 10, 2023
PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer Trial in Changchun (Drug: Toripalimab,
Recruiting
- PD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer
- Drug: Toripalimab, FLOT(Docetaxel+oxaliplatin+leucovorin+5-FU)
-
Changchun, Ji Lin, ChinaFirst Hospital of Jilin University
Jul 18, 2022
Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)
Completed
- Recurrent/Metastatic Gastric Cancer
- Nivolumab, Paclitaxel
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Sep 9, 2022
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in China (Atezolizumab, Trastuzumab, Capecitabine)
Recruiting
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Atezolizumab
- +3 more
-
Beijing, China
- +9 more
Mar 11, 2022
Advanced Solid Tumor Trial in Chengdu (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)
Not yet recruiting
- Advanced Solid Tumor
- Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Oct 9, 2023
Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)
Recruiting
- Biliary Tract Cancer
- +2 more
-
Shanghai, ChinaZhongshan hospital, Fudan University
Aug 12, 2023
Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC Trial run by the NCI (N-803, Pembrolizumab, PD-L1 t-haNK)
Recruiting
- Gastroesophageal Junction (GEJ) Cancers
- Advanced HNSCC
- N-803
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 26, 2023
Serplulimab,Gastric Cancer, Adjuvant Therapy Trial in Shanghai (Serplulimab, Docetaxel, S1)
Recruiting
- Serplulimab,Gastric Cancer, Adjuvant Therapy
- Serplulimab
- +2 more
-
Shanghai, ChinaZhang Zizhen
Mar 3, 2023
Gastric Cancer Trial (DP303c treatment, DP303c treatment(second-line of HER2-positive), DP303c treatment (third-line of
Not yet recruiting
- Gastric Cancer
- DP303c treatment
- +4 more
- (no location specified)
Mar 30, 2021
Non Small Cell Lung Cancer Trial in Pittsburgh (Fecal Microbiota Transplant (FMT), Pembrolizumab)
Not yet recruiting
- Non Small Cell Lung Cancer
- Fecal Microbiota Transplant (FMT)
- Pembrolizumab
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Dec 20, 2022
Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS=1) Trial (SG001 injection, Paclitaxel, Cisplatin)
Not yet recruiting
- Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
- SG001 injection
- +5 more
- (no location specified)
Jan 27, 2023
Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)
Not yet recruiting
- Cervical Cancer
- Recombinant humanized anti-PD-1 monoclonal antibody injection
- +4 more
-
Wuhan, Hubei, ChinaTongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023
Gastric Adenocarcinoma Trial (cadonilimab combined +paclitaxel (albumin-bound))
Not yet recruiting
- Gastric Adenocarcinoma
- cadonilimab combined +paclitaxel (albumin-bound)
- (no location specified)
Nov 1, 2023
Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)
Not yet recruiting
- Lung Cancer
- Centipeda minima+PD-1/PD-L1 inhibitor
- PD-1/PD-L1 inhibitor
- (no location specified)
Feb 17, 2023
Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Unresectable Breast Carcinoma Trial in Aurora (Nab-paclitaxel,
Withdrawn
- Triple Negative Breast Cancer
- +4 more
- Nab-paclitaxel
- +3 more
-
Aurora, ColoradoUniversity of Colorado Hospital
Dec 2, 2022
Advanced or Metastatic Urothelium Cancer Trial in Beijing (MRG002, Docetaxel Injection, Paclitaxel Injection)
Not yet recruiting
- Advanced or Metastatic Urothelium Cancer
- MRG002
- +4 more
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Feb 22, 2023
Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)
Recruiting
- Digestive System Cancers
- KN046
- +2 more
-
Beijing, ChinaPeking University Cancer Hospital
Oct 25, 2023
Urothelial Carcinoma Bladder, PD-1 Inhibitor Trial in Shanghai (Tislelizumab, Gemcitabine, Cisplatin)
Recruiting
- Urothelial Carcinoma Bladder
- PD-1 Inhibitor
- Tislelizumab
- +2 more
-
Shanghai, Shanghai, ChinaRenji Hospital, School of Medicine, Shanghai Jiao Tong Universit
Aug 15, 2022
Gastric Cancer, HER2-low-expressing Gastric Cancer Trial in Shanghai (Disitamab Vedotin, Toripalimab)
Recruiting
- Gastric Cancer
- HER2-low-expressing Gastric Cancer
- Disitamab Vedotin
- Toripalimab
-
Shanghai, ChinaShanghai East Hospital
Oct 9, 2023
NSCLC Trial (pembrolizumab, carboplatin, paclitaxel)
Active, not recruiting
- Non-small Cell Lung Cancer
- pembrolizumab
- +3 more
- (no location specified)
Aug 18, 2022
Gastric or Gastroesophageal Junction Adenocarcinoma Trial in Nanjing (neoadjuvant chemo-hypofractionated radiotherapy plus PD-1
Active, not recruiting
- Gastric or Gastroesophageal Junction Adenocarcinoma
- neoadjuvant chemo-hypofractionated radiotherapy plus PD-1 antibody (Tislelizumab)
-
Nanjing, Jiangsu, ChinaJiangsu Cancer Hospital
Jul 4, 2023
Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin
Recruiting
- Gastric Cancer
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Oct 22, 2023
